PMID- 30487953
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1948-5204 (Print)
IS  - 1948-5204 (Electronic)
VI  - 10
IP  - 11
DP  - 2018 Nov 15
TI  - Comparison of efficacy and safety between standard-dose and modified-dose 
      FOLFIRINOX as a first-line treatment of pancreatic cancer.
PG  - 421-430
LID - 10.4251/wjgo.v10.i11.421 [doi]
AB  - AIM: To directly compare the efficacy and toxicity of standard-dose FOLFIRINOX 
      (sFOLFIRINOX) and modified-dose FOLFIRINOX (mFOLFIRINOX, 75% of standard-dose) 
      for pancreatic cancer. METHODS: One hundred and thirty pancreatic cancer patients 
      who received sFOLFIRINOX (n = 88) or mFOLFIRINOX (n = 42) as their first-line 
      chemotherapy from January 2013 to July 2017 were retrospectively reviewed. For 
      efficacy analysis, the objective response rate (ORR), disease control rate (DCR), 
      progression-free survival (PFS), and overall survival (OS) were evaluated and 
      compared using Pearson's chi-square test, Kaplan-Meier plot and log-rank test. 
      The adverse events (AEs) were evaluated, and severe (>/= grade 3) AEs rates of the 
      two groups were compared for toxicity analysis. RESULTS: The mFOLFIRINOX group 
      included more female patients (30.7% vs 57.1%; P = 0.004) and older patients [age 
      (median), 57 vs 63.5; P = 0.018] than the sFOLFIRINOX group. In the efficacy 
      analysis, the ORR and DCR were not significantly different between the two groups 
      (ORR: 39.8% vs 35.7%; P = 0.656; DCR: 80.7% vs 83.3%; P = 0.716). The median PFS 
      and OS were also not different between the groups (PFS: 8.7 mo vs 8.1 mo, P = 
      0.272; OS: 13.9 mo vs 13.7 mo, P = 0.476). In the safety analysis with severe 
      AEs, the rates of neutropenia (83.0% vs 66.7%; P = 0.044), anorexia (48.9% vs 
      28.6%; P = 0.029) and diarrhea (13.6% vs 0.0%; P = 0.009) were markedly lower in 
      the mFOLFIRINOX group. CONCLUSION: mFOLFIRINOX showed comparable efficacy but 
      better safety compared to sFOLFIRINOX. If clinically necessary, initiating 
      FOLFIRINOX with 75% of the standard-dose can alleviate toxicity concerns without 
      compromising efficacy.
FAU - Kang, Huapyong
AU  - Kang H
AD  - Division of Gastroenterology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seodaemun-gu, Seoul 03722, South Korea.
FAU - Jo, Jung Hyun
AU  - Jo JH
AD  - Division of Gastroenterology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seodaemun-gu, Seoul 03722, South Korea.
FAU - Lee, Hee Seung
AU  - Lee HS
AD  - Division of Gastroenterology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seodaemun-gu, Seoul 03722, South Korea.
FAU - Chung, Moon Jae
AU  - Chung MJ
AD  - Division of Gastroenterology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seodaemun-gu, Seoul 03722, South Korea.
FAU - Bang, Seungmin
AU  - Bang S
AD  - Division of Gastroenterology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seodaemun-gu, Seoul 03722, South Korea.
FAU - Park, Seung Woo
AU  - Park SW
AD  - Division of Gastroenterology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seodaemun-gu, Seoul 03722, South Korea.
FAU - Song, Si Young
AU  - Song SY
AD  - Division of Gastroenterology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seodaemun-gu, Seoul 03722, South Korea.
FAU - Park, Jeong Youp
AU  - Park JY
AD  - Division of Gastroenterology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seodaemun-gu, Seoul 03722, South Korea. sensass@yuhs.ac.
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Gastrointest Oncol
JT  - World journal of gastrointestinal oncology
JID - 101532470
PMC - PMC6247105
OTO - NOTNLM
OT  - Adenocarcinoma
OT  - Adverse event
OT  - Chemotherapy
OT  - Dose modification
OT  - FOLFIRINOX
OT  - Pancreatic cancer
COIS- Conflict-of-interest statement: All authors declare no conflicts-of-interest 
      related to this article.
EDAT- 2018/11/30 06:00
MHDA- 2018/11/30 06:01
PMCR- 2018/11/15
CRDT- 2018/11/30 06:00
PHST- 2018/08/06 00:00 [received]
PHST- 2018/09/07 00:00 [revised]
PHST- 2018/10/10 00:00 [accepted]
PHST- 2018/11/30 06:00 [entrez]
PHST- 2018/11/30 06:00 [pubmed]
PHST- 2018/11/30 06:01 [medline]
PHST- 2018/11/15 00:00 [pmc-release]
AID - 10.4251/wjgo.v10.i11.421 [doi]
PST - ppublish
SO  - World J Gastrointest Oncol. 2018 Nov 15;10(11):421-430. doi: 
      10.4251/wjgo.v10.i11.421.